司美格魯肽改善糖尿病與腎臟病患者的日常生活
Semaglutide Improves Daily Life for Patients with Diabetes and Kidney Disease
Updated at: June 4, 2026 at 01:20 PM
對於同時患有第二型糖尿病與慢性腎臟病的成年人來說，生活往往像是與健康局限搏鬥的長期抗爭。
For adults managing both type 2 diabetes and chronic kidney disease, life can often feel like a constant struggle with health limitations.
然而，來自里程碑式「FLOW試驗」令人振奮的新數據帶來了希望。
However, exciting new data from the landmark FLOW trial brings a message of hope.
該研究在第63屆歐洲腎臟協會(ERA)大會上發表，結果顯示，每週一次的司美格魯肽(Semaglutide)不僅能保護腎功能，還能顯著提升患者的整體生活品質。
Presented at the 63rd ERA Congress, the study revealed that once-weekly semaglutide does more than just protect kidney function; it significantly enhances a patient's overall quality of life.
結果顯示，安慰劑組患者在兩年內的健康效用評分下降，而接受司美格魯肽治療的患者則保持穩定。
Results showed that while patients on a placebo saw their health utility scores decline over two years, those treated with semaglutide maintained stability.
患者回報在行動力、自我照護與疼痛管理方面均有所改善。
Patients reported improvements in mobility, self-care, and pain management.
對於醫師與患者而言，這項證據強調了治療目標不僅應包含延長壽命，還應重視實際的日常生活品質，證明司美格魯肽是患者面對這些複雜病症時至關重要的工具。
For both doctors and patients, this evidence highlights that treatment goals should include not just longevity, but the actual quality of daily life, proving semaglutide is a vital tool for those navigating these complex conditions.
